Document is current
Any future updates will be listed below
-
Authors
Lon, Hoi-Kei
Hibma, Jennifer
Jiang, Sibo
Sullivan, Sharon
Vandendries, Erik
Skoura, Athanasia
Wang, Diane
Elmeliegy, Mohamed https://orcid.org/0000-0002-9825-5890
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03269136 at ClinicalTrials.govnct04798586 at ClinicalTrials.govDocuments that mention this clinical trial
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20021
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01168-y
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
Documents that mention this clinical trial
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01168-y
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 7 July 2025
First Online: 18 August 2025
Declarations
:
: This study was funded by Pfizer.
: H.K.L., J.H., S.J., S.S., E.V., A.S., D.W., and M.E. report employment and stock ownership at Pfizer.
: All studies reported here are being conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice. The study protocols and relevant documents were approved by independent institutional review boards or ethics committees at each investigative center.
: All patients provided written informed consent.
: Not applicable.
: Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this article. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: Not applicable.
: All authors were involved in the trial conception/design, or the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript and approved the final version.
